Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.

Tamma, Pranita D; Harris, Patrick N A; Mathers, Amy J; Wenzler, Eric; Humphries, Romney M

Tamma, Pranita D; Harris, Patrick N A; Mathers, Amy J; Wenzler, Eric; Humphries, Romney M.

Afiliación

Tamma PD; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Harris PNA; Faculty of Medicine, UQ Center for Clinical Research, Royal Brisbane and Women's Hospital Campus, University of Queensland, Brisbane, Australia.
Mathers AJ; Department of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA.
Wenzler E; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.
Humphries RM; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Clin Infect Dis ; 77(11): 1585-1590, 2023 11 30.

Article en En | MEDLINE | ID: mdl-36001445

Asunto(s)

Antibacterianos; Laboratorios Clínicos; Humanos; Antibacterianos/uso terapéutico; Antibacterianos/farmacocinética; Combinación Piperacilina y Tazobactam; Pruebas de Sensibilidad Microbiana

Palabras clave

CLSI; antimicrobial susceptibility testing; pharmacodynamics; pharmacokinetics; susceptibility

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Laboratorios Clínicos / Antibacterianos Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google